ELI LILLY EAST SA ,   Switzerland

A solution for subcutaneous administration of 250 μg / ml

In the case of Eli Lilly and Company Limited, UK, it is stated:

Tablets, film-coated, 2.5 mg, 5 mg, 7.5 mg and 10 mg.

In the case of the production of Lilly SA, Spain or Lilly del Caribe Inc., Puerto Rico, it is indicated:

Tablets, film-coated, 5 mg and 10 mg.

Powder for suspension for intramuscular injection 210 mg, 300 mg or 405 mg complete with a solvent.

Tablets are dispersible, 5 mg, 10 mg.

Lyophilizate for the preparation of a solution for intravenous and intramuscular injection 1 g.

Tablets, film-coated 2.5 mg, 5 mg.

For 14 tablets in a blister, consisting of aluminum laminated foil and PVC / PE / PCTFE film. For 1 or 2 blisters, together with the instructions for use, put in a pack of cardboard.

Capsules 10 mg, 18 mg, 25 mg, 40 mg and 60 mg.

A solution for subcutaneous administration, 0.75 mg / 0.5 ml or 1.5 mg / 0.5 ml.

A solution for subcutaneous administration of 250 μg / ml in a 3 ml syringe pen. and 2.4 ml. One syringe pen together with the instruction for use of the drug and the Manual on the use of the syringe pen in a pack of cardboard.

Suspension for subcutaneous administration, 100 IU / ml.

Suspension for subcutaneous administration, 100 IU / ml.

Suspension for subcutaneous administration, 100 IU / ml.

Solution for injection, 100 IU / ml.

Concentrate for the preparation of a solution for infusions of 10 mg / ml.

Tablets, film-coated, 5 mg and 10 mg.